Metabolism and cancer
PRINCIPAL INVESTIGATORS
- Albert Tauler Girona
- Antonio Gentilella
POSTDOCTORAL RESEARCHERS
- Pedro Fuentes Varela
- Mauvezin, Caroline
PREDOCTORAL RESEARCHERS
- Flavia Iannizzotto
- Carolina Martínez Herráez
SCIENTIFIC SUPPORT
- Pau Bosch Crespo
STUDENTS
- Alba Olaso Llorca
Cancer
Oncobell
Scientific production
4
PAPERS
Impact factor: 67,184
4 PUBLICATIONS IN FIRST DECILE
4 PUBLICATIONS IN FIRST QUARTILE
3 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Domostegui A, Peddigari S, Mercer CA, Iannizzotto F, Rodriguez ML, Garcia Cajide M, Amador V, Diepstraten ST, Kelly GL, Salazar R, Kozma SC, Kusnadi EP, Kang J, Gentilella A, Pearson RB, Thomas G, Pelletier J.
- Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death. Blood. 2021;137(24):3351-3364. doi:10.1182/blood.2020007452. IF:22,11.
- Almacellas E, Pelletier J, Day C, Ambrosio S, Tauler A, Mauvezin C. Lysosomal degradation ensures accurate chromosomal segregation to prevent chromosomal instability. Autophagy. 2021;17(3):796-813. doi:10.1080/15548627.2020.1764727. IF:16,02.
- Fuentes P, Pelletier J, Martinez Herráez C, Diez Obrero V, Iannizzotto F, Rubio T, Garcia Cajide M, Menoyo S, Moreno V, Salazar R, Tauler A, Gentilella A. The 40S-LARP1 complex reprograms the cellular translatome upon mTOR inhibition to preserve the protein synthetic capacity. Sci Adv. 2021;7(48):doi:10.1126/sciadv.abg9275. IF:14,14.
Diesch J, Le Pannérer MM, Winkler R, Casquero R, Muhar M, van der Garde M, Maher M, Herráez CM, Bech Serra JJ, Fellner M, Rathert P, Brooks N, Zamora L, Gentilella A, de la Torre C, Zuber J, Götze KS, Buschbeck M. Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis. Nat. Commun. 2021;12(1):6060-6060. doi:10.1038/s41467-021-26258-z. IF:14,92.
Research highlights
PROJECTS
9 Competitive projects
1 Non-competitive project
NETWORKS
AGAUR (GRC)
Selected projects
- 20PSJ024. Overcoming resistance to therapy in Colorectal Cancer by attacking the 40S-LARP1-5™TOPs anabolic reservoir. (LABAE20040GENT). AECC. 2020-2023. IP:GENTILELLA,ANTONIO.
- 19MEC009. AYUDAS PARA CONTRATOS PREDOCTORALES PARA LA FORMACIÓN DE DOCTORES 2018. (PRE2018-086310). MINISTERIO DE CIENCIA E INNOVACIÓN (MICINN). 2019-2023. IP:GENTILELLA,ANTONIO.
- 18MEC006. Papel de los complejos 40S-LARP1 y IRBC en el cancer colorectal dirigido por c-myc. (SAF2017-84301-P). MINISTERIO DE CIENCIA E INNOVACIÓN (MICINN). 2018-2021. IP:GENTILELLA,ANTONIO.
- 18MEC018. Alteración de la actividad v-ATPasa y el tráfico lisosomal como terapia contra el cáncer. 2018-2021. IP:TAULER GIRONA,ALBERT.
- 15PRV001. NEW THERAPEUTIC STRATEGIES FOR RESISTANT COLORECTAL CANCER. (GCB14142035THOM). AECC; FUNDACIO IDIBELL; ISCIII. 2015-2022. IP:THOMAS,GEORGE.